ReviewGenes & diseases2025
The epigenetic regulatory network of long noncoding RNAs in hepatocellular carcinoma.
Review in Genes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A Comparative Analysis of the Methylation Status of Non-Coding RNA Promoters in Fibroid and Matched Myometrium.International journal of molecular sciences · 2026Article
- An Energy Model Based on Molecular Structure for Predicting Histone Modification Levels at lncRNA Promoter Regions in HepG2 Cells.International journal of molecular sciences · 2026Article
- DNASE1L3 functions as a significant metastatic suppressor by attenuating MYH9/β-catenin/c-Jun/LncRNA-KDM4A-induced E-cadherin ubiquitination degradation in nasopharyngeal carcinoma.Cellular & molecular biology letters · 2026Article
- Review
- Role of non-coding RNAs in OOncology letters · 2026Review
- The lncRNA-DNA Methylation Axis in Hepatocellular Carcinoma: Mechanisms, Epigenetic Plasticity, and Biological Implications.Biology · 2026Review
- Blood-based epigenetic biomarkers in rheumatoid arthritis: current knowledge and future perspectives.Frontiers in immunology · 2026Review
- Regulatory roles of LncRNAs in colorectal cancer immune evasion: current concepts and future perspectives.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long noncoding RNAs (lncRNAs) are endogenous noncoding RNAs exceeding 200 bases in length that are prevalent in malignant tumors and are closely associated with the onset and progression of hepatocellular carcinoma. The synthesis of lncRNAs exhibits similarities to that of protein-coding transcripts, which is regulated by epigenetic modifications. Recent research has highlighted the significant regulatory role of epigenetic modifications in the transcription of lncRNA genes in hepatocellular carcinoma. This review outlines the impact of epigenetic modifications, including DNA methylation, histone modification (methylation and acetylation), RNA modification, and microRNAs on the transcription of lncRNA genes in hepatocellular carcinoma and delves into the underlying mechanisms by summarizing how these lncRNA genes contribute to the development and progression of hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.